HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK CBD Industry Embraces Trading Standards Partnership As Compliance Deadline Looms

Executive Summary

UK CBD industry association, the ACI, joins others in forming partnerships with local authorities responsible for enforcing the new rules, which require all CBD food supplements on the market to hold a validated novel food application with the FSA. However, how effective enforcement will be in practice remains to be seen. 

You may also be interested in...

Europe's CBD Market In 2020: Narcotic Vs Novel Food

INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.

UK Retailers Take Divergent Paths With CBD Enforcement On Horizon

Predicted to be worth at least half a billion dollars by the end of the year, the UK's CBD market shows no sign of slowing down. However, regulatory and consumer confusion is distributing the benefits of this growth unevenly, and holding back mass market retailers from leaning in fully, according to a HBW Insight analysis. 

Looking To Enter The UK CBD Market Before 31 March? It Won't Be Easy

How can you enter the fast-growing UK CBD market before March 2021? There is only one way, according to Global Regulatory Services' CBD expert Greer Deal, who explained the situation at a recent Medilink East Midlands webinar.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts